SCHEMBL4820035

SCHEMBL4820035

COc1ccc2[nH]c(C=CN(C)C)c(C=O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 5/20 0.47
MAPT P10636 3/20 0.47
HSD17B10 Q99714 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.47
GFER P55789 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
AHR P35869 1/20 0.43
HPGD P15428 3/20 0.43
ABCG2 Q9UNQ0 1/20 0.42
PIKFYVE Q9Y2I7 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
HTR1A P08908 1/20 0.40
SLC6A2 P23975 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1E P28566 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820027 1.00 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL4824413 0.81 KIF11 (0.40) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL4824528 0.81 LMNA (0.40) ALDH1A1MAPTHSD17B10CYP1A2CYP2C19
SCHEMBL4824418 0.81 KIF11 (0.40) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL4824535 0.81 LMNA (0.40) ALDH1A1MAPTHSD17B10CYP1A2CYP2C19
SCHEMBL31429037 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL1428940 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL1429044 0.75 AHR (0.55) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL8400871 0.75 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL29361281 0.75 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465738-B2 Compounds useful as promoters of SMN2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-12-16 US disclosed
US-20050065173-A1 Compounds useful as promoters of SMN2 VERTEX PHARMACEUTICALS INCORPORATED 2005-03-24 US disclosed
WO-2004113305-A2 DIAMINO SUBSTITUTED QUINAZOLINE DERIVATIVES AS PROMOTERS OF SMN2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065173-A1 Compounds useful as promoters of SMN2 SMN1; SMN2, NSUN2, MECP2 ALDH1A1 1813/4885KDM4E 1457/4885MAPT 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.